VEGFA mediates traditional EGFR-TKI resistance in non-small cell lung cancer with EGFR exon 20 insertions

被引：0
|
作者：
Yang, Yaning
Liu, Chengming
Yang, Guangjian
Xu, Haiyan
Lei, Siyu
Wang, Yan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
VEGFA; targeted therapy; resistance; EGFR exon 20 insertions; non-small cell lung cancer;
D O I：
10.1158/1538-7445.AM2024-3263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3263
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
    Peng, Yanmei
    Cui, Huijuan
    Liu, Zhe
    Liu, Daiwei
    Liu, Fan
    Song, Yazhong
    Duan, Hua
    Qiu, Yuqin
    Li, Qiang
    ONCOTARGETS AND THERAPY, 2017, 10 : 2289 - 2295
  • [42] Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
    Reita, Damien
    Pabst, Lucile
    Pencreach, Erwan
    Guerin, Eric
    Dano, Laurent
    Rimelen, Valerie
    Voegeli, Anne-Claire
    Vallat, Laurent
    Mascaux, Celine
    Beau-Faller, Michele
    CANCERS, 2021, 13 (19)
  • [43] Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
    Zhimin Zhang
    Xiaojuan Lian
    Wei Xie
    Jin Quan
    Maojun Liao
    Yan Wu
    Zhen-Zhou Yang
    Ge Wang
    Scientific Reports, 10
  • [44] MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
    Li, Bing
    Ren, Shengxiang
    Li, Xuefei
    Wang, Yongsheng
    Garfield, David
    Zhou, Songwen
    Chen, Xiaoxia
    Su, Chunxia
    Chen, Mo
    Kuang, Peng
    Gao, Guanghui
    He, Yayi
    Fan, Lihong
    Fei, Ke
    Zhou, Caicun
    Schmit-Bindert, Gerald
    LUNG CANCER, 2014, 83 (02) : 146 - 153
  • [45] The reversible resistance mechanisms of second generation EGFR-TKI, Dacomitinib, in non-small cell lung cancer.
    Haga, Yuya
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2023, 114 : 1488 - 1488
  • [46] EGFR exon 20 insertion mutations in non-small cell lung cancer
    Wang, Fenfang
    Li, Chenghui
    Wu, Qihuan
    Lu, Hongyang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
  • [47] Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
    Zhang, Zhimin
    Lian, Xiaojuan
    Xie, Wei
    Quan, Jin
    Liao, Maojun
    Wu, Yan
    Yang, Zhen-Zhou
    Wang, Ge
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [48] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    LUNG CANCER, 2015, 88 (01) : 74 - 79
  • [50] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 83 - 84
12345